Table 1.

Univariate Analysis of Clinical Factors to Predict Survival.

Parameter (n) Median Survival P Value
Gender Female (n=63) 15.4 months 0.88
Male (n=102) 15.2 months

Cortical Involvement Yes (n=121) 15.4 months 0.044
No (n= 44) 13.2 months

Extent of Resection Total (n=105) 16.8 months <0.0001 between total and biopsy only group
Subtotal (n=14) 16.7 months
Biopsy only (n=44) 9.2 months

Radiotherapy With and Without TMZ RT+TMZ (n=152) 15.3 months 0.79
RT only (n=13) 14.7 months

ECOG Performance Status PS-0 (n=56) 19.6 months <0.005 for all groups
PS-1 (n=47) 18.2 months
PS-2 (n=36) 11.4 months
PS-3 (n=18) 9.6 months
PS-4 (n=8) 5.8 months

Hypertension Yes (n=71) 11.7 months 0.05
No (n=94) 16.7 months

Diabetes Mellitus Yes (n=25) 10.16 months 0.016
No (n=140) 15.76 months

Seizures at Time of Diagnosis Yes (n=46) 16.8 months 0.16
No (n=119) 14.26 months

Vomiting at Time of Diagnosis Yes (n=18) 15.7 months 0.21
No (n=147) 15.2 months

Visual Disturbances at Time of Diagnosis Yes (n=14) 23.6 months 0.015
No (n=151) 14.2 months

Headaches at Time of Diagnosis Yes (n=84) 15.9 months 0.02
No (n=81) 12.9 months

Motor Deficit at Time of Diagnosis Yes (n=60) 15.4 months 0.17
No (n=105) 15.2 months

Sensory Deficit at Time of Diagnosis Yes (n=9) 15.4 months 0.84
No (n=156) 15.2 months

Cognitive Impairment/Confusion at Time of Diagnosis Yes (n=57) 12.5 months 0.04
No (n=108) 15.8 months

Steroid-dependent Yes (n=157) 15.2 months 0.45
No (n=8) 16.9 months

RT, radiotherapy; RT+TMZ, adjuvant temozolomide and radiotherapy according to Stupp et al.1

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2015 October; 6(4): e0039. ISSN: 2076-9172
Published online 2015 October 26. doi: 10.5041/RMMJ.10224.